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Cisplatin is a highly effective chemotherapeutic drug used in the treatment of several 
tumors. It is a DNA-damaging agent that induces apoptosis of rapidly proliferating cells, 
an important factor underlying its therapeutic efficacy. Unfortunately, cellular resistance 
occurs often. A large fraction of tumor cells harbor mutations in p53, contributing to 
defects in apoptotic pathways and drug resistance. However, cisplatin-induced apoptosis 
can also occur in p53 deficient cells; thus, elucidation of the molecular mechanism 
involved will potentially yield new strategies to eliminate tumors that have defects in the 
p53 pathway. 
Most of the studies in this field have been conducted in cultured mammalian cells, not 
amenable to systematic genetic manipulation. Therefore, we aimed to establish a 
simplified model to study cisplatin-induced apoptosis using the yeast Saccharomyces 
cerevisiae. Our results indicate cisplatin induces an active form of cell death in yeast, as 
this process was partially dependent on new protein synthesis and did not lead to loss of 
membrane integrity. Preliminary studies of apoptotic markers revealed mitochondrial 
fragmentation and chromatin condensation after cisplatin exposure. Deletion of Yca1p, 
the yeast metacaspase, did not protect cells from cisplatin-induced cell death, although 
exposure of yeast cells to cisplatin resulted in an increase in proteolytic activity that was 
inhibited in vitro by MG132, a commonly used proteasome inhibitor. In vivo, co-
incubation with MG132 increased resistance to cisplatin and, accordingly, yeast strains 
deficient in proteasome proteolytic activity were more resistant to cisplatin than wild type 
strains. Proteasome inhibitors induce apoptosis in various cell types, whereas in others 
they prevent apoptosis induced by different stimuli. Our results indicate inhibition of the 
proteasome protects from cisplatin-induced apoptosis in budding yeast. The molecular 
mechanism involved is under characterization.  
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